Latin American countries lined up for J&J's COVID-19 vaccine trial
With Latin America currently seen as the epicenter of the coronavirus pandemic, patients from six countries in the region are to participate in a Phase III trial of one of the most advanced vaccine candidates.
US healthcare giant Johnson & Johnson’s (NYSE: JNJ) Janssen unit is one of the companies with a vaccine in a Phase III trial. The vector-based candidate for prevention of SARS-CoV-2, termed Ad26.COV2.S, has been developed with the assistance of the Biomedical Advanced Research and Development Authority, part of the US Department of Health and Human Services.
The US authorities have committed more than $1 billion for the vaccine, which will be provided on a global not-for-profit basis for emergency pandemic use.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze